FIG 2.
Activity of LDV against other classes of DAA RAVs. The indicated RAVs were evaluated by introducing them into wild-type genotype 1a or 1b replicons followed by transient transfection. Fold resistance was calculated as the ratio of RAV EC50 to wild-type EC50. Values represent the means from two or more independent experiments. LDV is fully active against NS3 protease inhibitor RAVs and NS5B nucleoside and NS5B nonnucleoside inhibitor RAVs. LDV is less effective against NS5A RAVs selected in genotype 1a patients during 3-day monotherapy in a phase 1 study.